Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00098
|
|||||
Drug Name |
Glucose-6-phosphate
|
|||||
Synonyms |
299-31-0; 6-O-phosphono-D-glucopyranose; AC1L1LI0; AC1Q28E3; CHEBI:4170; D-Glucopyranose 6-phosphoric acid; D-glucopyranose 6-phosphate; D-glucopyranose, 6-(dihydrogen phosphate); D-glucose-6-P; D-glucose-6P; GTPL4647; Glc6P; Glucose 6-(dihydrogen phosphate); Glucose 6-phosphate; Robison ester; SCHEMBL48379; a-D-glucose 6- phosphate; {[(2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | High blood glucose [ICD11: 5C61.5] | Phase 1 | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C6H13O9P
|
|||||
Canonical SMILES |
C(C1C(C(C(C(O1)O)O)O)O)OP(=O)(O)O
|
|||||
InChI |
InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6?/m1/s1
|
|||||
InChIKey |
NBSCHQHZLSJFNQ-GASJEMHNSA-N
|
|||||
CAS Number |
CAS 56-73-5
|
|||||
Pharmaceutical Properties | Molecular Weight | 260.14 | Topological Polar Surface Area | 157 | ||
Heavy Atom Count | 16 | Rotatable Bond Count | 3 | |||
Hydrogen Bond Donor Count | 6 | Hydrogen Bond Acceptor Count | 9 | |||
XLogP |
-4.2
|
|||||
PubChem CID | ||||||
PubChem SID | ||||||
ChEBI ID |
ChEBI:4170
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | G3PP | Transporter Info | Glycerol-3-phosphate permease | Substrate | [2] | |
G6PT | Transporter Info | Glucose-6-phosphate translocase | Substrate | [3] | ||
References | ||||||
1 | ClinicalTrials.gov (NCT01205178) G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine) | |||||
2 | SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011;6(9):e23157. | |||||
3 | A novel mutation (A148V) in the glucose 6-phosphate translocase (SLC37A4) gene in a Korean patient with glycogen storage disease type 1b. J Korean Med Sci. 2005 Jun;20(3):499-501. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.